EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunohistochemical Characterisation of Mismatch Repair Proteins in Feline Cancers: A Pilot Study Using Validated Cross‐Reactive Antibodies

Shoma Nishibori, Masashi Sakurai iD, Yumiko Kagawa iD, Kazuo Nishigaki, Takayuki Nakagawa iD, Sakuya Inanaga, Masaya Igase iD, Takuya Mizuno iD

Veterinary and Comparative Oncology · 2026-12 · 24 (4) · 809-818

DOI: 10.1111/vco.70105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, online erschienen am 16.08.2026. Verfasst von Shoma Nishibori und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Diagnostics and Therapeutics, Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Yamaguchi, Japan. Hauptthemen laut MEDLINE: Immunohistochemistry, DNA Mismatch Repair, Cat Diseases, Neoplasms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA mismatch repair (MMR) deficiency is a clinically important biomarker in human oncology, yet its relevance in feline neoplasia remains poorly understood due to limited characterisation and the absence of validated reagents. In this study, we established a practical immunohistochemistry (IHC) approach for evaluating feline MMR proteins by confirming the cross‐reactivity of anti‐human MLH1, MSH2 and MSH6 antibodies using CRISPR/Cas9‐engineered feline tumour cell lines lacking each target gene. Using these validated antibodies, we conducted a pilot screening to assess MMR protein expression in 83 feline tumours and observed variable reductions or losses of MLH1, MSH2 and MSH6 across several tumour types. Notably, MLH1 expression was lost in all melanoma cases (6/6, 100%) and in most osteosarcomas (14/15, 93%), indicating that MMR perturbations may be particularly relevant in these malignancies. These findings provide the first analytically validated framework for assessing MMR proteins in feline oncology and suggest that MMR dysregulation may be more widespread than previously recognised. Although the clinical sample size is limited, this initial pilot screening maps the preliminary landscape of feline MMR protein expression. Further large‐scale validation studies incorporating microsatellite instability testing, methylation analysis and genomic profiling are warranted to clarify the biological significance of these alterations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunohistochemistryDNA Mismatch RepairCat DiseasesNeoplasmsAnimalsCatsPilot ProjectsDNA-Binding ProteinsMutL Protein Homolog 1MutS Homolog 2 ProteinCross ReactionsCell Line, TumorAntibodies

Stichwörter der Autor:innen

cross‐reactive antibodyfeline tumourimmune biomarkersimmunohistochemistrymismatch repair

Substanzen

DNA-Binding ProteinsMutL Protein Homolog 1MutS Homolog 2 ProteinAntibodiesG-T mismatch-binding protein

Autor:innen und Institutionen

  • Laboratory of Molecular Diagnostics and Therapeutics, Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Yamaguchi, Japan.
  • Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Yamaguchi, Japan.
  • Division of Translational Research for One Medicine, Research Institute for Cell Design Medical Science, Yamaguchi University, Yamaguchi, Yamaguchi, Japan.
  • North Lab., Sapporo, Hokkaido, Japan.
  • Laboratory of Molecular Immunology and Infectious Disease, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Yamaguchi, Japan.
  • Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Masashi Sakurai, Yumiko Kagawa, Takayuki Nakagawa, Masaya Igase, Takuya Mizuno

Zitieren

APA

Nishibori, S., Sakurai, M., Kagawa, Y., Nishigaki, K., Nakagawa, T., Inanaga, S., Igase, M., & Mizuno, T. (2026). Immunohistochemical Characterisation of Mismatch Repair Proteins in Feline Cancers: A Pilot Study Using Validated Cross‐Reactive Antibodies. Veterinary and Comparative Oncology, 24(4), 809-818. https://doi.org/10.1111/vco.70105

Vancouver

Nishibori S, Sakurai M, Kagawa Y, Nishigaki K, Nakagawa T, Inanaga S, et al. Immunohistochemical Characterisation of Mismatch Repair Proteins in Feline Cancers: A Pilot Study Using Validated Cross‐Reactive Antibodies. Veterinary and Comparative Oncology. 2026;24(4):809-818. doi:10.1111/vco.70105

BibTeX
@article{Nishibori2026,
  author = {Nishibori, Shoma and Sakurai, Masashi and Kagawa, Yumiko and Nishigaki, Kazuo and Nakagawa, Takayuki and Inanaga, Sakuya and Igase, Masaya and Mizuno, Takuya},
  title = {Immunohistochemical Characterisation of Mismatch Repair Proteins in Feline Cancers: A Pilot Study Using Validated Cross‐Reactive Antibodies},
  journal = {Veterinary and Comparative Oncology},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {809--818},
  doi = {10.1111/vco.70105}
}
Kostenlos starten →